# Exome sequencing in 16 patients with pituitary stalk interruption syndrome: A monocentric study

Raja Brauner, Joelle Bignon-Topalovic, Anu Bashamboo, Ken Mcelreavey

<figure><img src="image_1.png" /></figure>

## To cite this version:

Raja Brauner, Joelle Bignon-Topalovic, Anu Bashamboo, Ken Mcelreavey. Exome sequencing in 16 patients with pituitary stalk interruption syndrome: A monocentric study. PLoS ONE, 2023, 18 (12), pp.e0292664. 10.1371/journal.pone.0292664. pasteur-04763116

HAL Id: pasteur-04763116

https://pasteur.hal.science/pasteur-04763116v1

Submitted on 1 Nov 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
RESEARCH ARTICLE

# Exome sequencing in 16 patients with pituitary stalk interruption syndrome: A monocentric study

Raja Brauner<sup>1*</sup>, Joelle Bignon-Topalovic<sup>2</sup>, Anu Bashamboo<sup>2</sup>, Ken McElreavey<sup>2</sup>

1 Pediatric Endocrinology Unit, Hôpital Fondation Adolphe de Rothschild and Université Paris Cité, Paris, France, 2 Human Developmental Genetic Unit, Institut Pasteur, Paris, France

* raja.brauner@wanadoo.fr

<figure><img src="image_3.png" /></figure>

## Abstract

Pituitary stalk interruption syndrome (PSIS) is a rare disorder characterized by an absent or ectopic posterior pituitary, absent or interrupted pituitary stalk and anterior pituitary hypoplasia on magnetic resonance imaging (MRI), as well in some cases a range of heterogeneous somatic anomalies. The triad can be incomplete. Here, we performed exome sequencing on 16 sporadic patients, aged 0.4 to 13.7 years diagnosed with isolated or complex PSIS. Growth hormone deficiency was isolated in 10 cases, or associated with thyrotropin deficiency in 6 others (isolated (2 cases), associated with adrenocorticotropin deficiency (1 case), gonadotropins deficiency (1 case), or multiple deficiencies (2 cases)). Additional phenotypic anomalies were present in six cases (37.5%) including four with ophthalmic disorders. In 13 patients variants were identified that may contribute to the phenotype. However, only a single individual carried a variant classified as pathogenic. This child presented with the typical clinical presentation of Okur-Chung neurodevelopmental syndrome due to a *CSNK2A1* missense variant. We also identified variants in the holoprosencephaly associated genes *GLI2* and *PTCH1*. A likely pathogenic novel splice site variant in the *GLI2* gene was observed in a child with PSIS and megacisterna magna. In the remaining 11 cases 26 variants in genes associated with pituitary development or function were identified and were classified of unknown significance. Compared with syndromic forms the diagnostic yield in the isolated forms of PSIS is low. Although we identified rare or novel missense variants in several hypogonadotropic hypogonadism genes (e.g. *FGF17*, *HS6ST1*, *KISS1R*, *CHD7*, *IL17RD*) definitively linking them to the PSIS phenotype is premature. A major challenge remains to identify pathogenic variants in cases with isolated PSIS.

<figure><img src="image_4.png" /></figure>

### OPEN ACCESS

**Citation:** Brauner R, Bignon-Topalovic J, Bashamboo A, McElreavey K (2023) Exome sequencing in 16 patients with pituitary stalk interruption syndrome: A monocentric study. PLoS ONE 18(12): e0292664. https://doi.org/10.1371/journal.pone.0292664

**Editor:** Nejat Mahdieh, Shaheed Rajaei Hospital: Rajaie Cardiovascular Medical and Research Center, ISLAMIC REPUBLIC OF IRAN

**Received:** July 31, 2023

**Accepted:** September 26, 2023

**Published:** December 14, 2023

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0292664

**Copyright:** © 2023 Brauner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and all novel variants are deposited with ClinVar (https://www.ncbi.nlm.nih.

## Introduction

Pituitary stalk interruption syndrome (PSIS) is a rare disorder characterized by the combination of specific findings in magnetic resonance imaging (MRI) including an absent or ectopic posterior pituitary, absent or interrupted pituitary stalk and anterior pituitary hypoplasia [1]. The triad can be incomplete. The consequences of PSIS are a series of anterior pituitary
gov/clinvar/) using accession codes VCV003852768, SCV000978577, SCV000978576, VCV000978570 or at the LOVD system at Global Variome Ltd (https://www.lovd.nl) with variant ID 0000933708.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

deficiencies including growth hormone (GH) deficiency that may be isolated or associated with other hormonal deficiencies including thyroid-stimulating hormone (TSH), adrenocorticotropin (ACTH) and/or luteinising hormone/follicle stimulating hormone (hypogonadotropie hypogonadism, HH). Posterior pituitary deficiency leading to central diabetes insipidus is very rare in PSIS.

Pathogenic or potentially pathogenic variants have been reported in PSIS associated with a wide range of genes involved in pituitary development or function [2–8] as well as genes associated with holoprosencephaly [9–11]. We previously analysed by exome sequencing 52 patients monitored for PSIS by the same pediatric endocrinologist and identified pathogenic and potentially pathogenic mutations in 39 patients [12]. Many of these cases where pathogenic variants were identified presented with complex phenotypes in addition to PSIS including seizures, neurodevelopmental disability, micropenis or cryptorchidism, which are usually considered as secondary to the pituitary deficiencies. However, we demonstrated they are likely due to pathogenic variants responsible for epilepsy, cerebral or cerebellum development, thyroid development or HH. This suggests that pathogenic variants are more likely to be identified in PSIS associated with other known genetic syndromes rather than as specific clinical entity.

Here, we analysed by exome sequencing 16 new patients diagnosed with PSIS. We identified pathogenic or likely pathogenic variants in only two patients, one presented with classical Okur-Chung neurodevelopmental syndrome and the other with isolated PSIS. Most of the patients in this series did not present with anomalies other than PSIS. Together with published data this suggests that obtaining a genetic diagnosis in cases of isolated PSIS will remain challenging. This is due to both the rarity of the phenotype and lack of familial cases which hinders formal genetic analysis as well as the lack of knowledge on the genetic pathways involved in pituitary formation and development.

# Materials and methods

## Patients

The diagnosis of PSIS was made on MRI if the patient present 1) an ectopic or absent posterior pituitary gland and/or 2) an interrupted, not seen, thin or malformed pituitary stalk, with or without hypoplasia or aplasia of the anterior pituitary gland. All patients had an ectopic posterior pituitary gland on MRI, except two patients where it was not seen and one with posterior pituitary gland in normal position but interrupted pituitary stalk (case 7). Thus, the pituitary stalk was defined as interrupted (n = 5), not seen (n = 5), thin (n = 3), malformed (n = 1) and normal (n = 2). The anterior pituitary gland height was measured on the midline T1 weighted scan [1]. It was low (n = 9), normal at 4 mm (n = 5) and not measured (n = 2).

This retrospective single-center study was performed in 16 individuals (13 boys and 3 girls). Thus, among the 98 PSIS patients monitored for hypothalamic-pituitary deficiency by a senior pediatric endocrinologist (R. Brauner) in a university hospital between 1978 and 2021 (43 years), 68 have a DNA sample available for ES. The results of ES of 52 of them were previously reported [12]. The data were accessed for the present work between January 2020 and December 2022.

## Methods

The pituitary evaluation and follow-up were conducted as previously described [13]. Hypoglycemia was defined as a blood glucose concentration below 3 mmol/L after 2 days of age. Decreased growth rate was defined as a height velocity during the previous year of more than one standard deviation score below the mean for chronological age or decrease in height
standard deviation of more than 0.5 over 1 year in children older than 2 years. Micropenis was
defined as a penis length of less than 30 mm.

The criterion for diagnosing GH deficiency was a GH peak response of less than 20 mU/L or 6.7 ng/mL after two pharmacological stimulation tests or during spontaneous hypoglycemia, excluding the response to GH-releasing hormone, with low insulin-like growth factor 1 concentration. As we used various GH assays over the study period, we expressed the GH peak concentration in mU/L using conversion factors (ng/mL to mU/L) that were specific of the international standard used to calibrate the GH assay. TSH deficiency was diagnosed by plasma free thyroxin below 12 pmol/L. ACTH deficiency was diagnosed by basal plasma cortisol concentrations at 8 a.m. below 40 ng/mL (110 nmol/L) in neonates and below 80 ng/mL (220 nmol/L) in older children, with no increase during hypoglycemia and low/normal ACTH concentration. HH was diagnosed by the absence of pubertal development at 13 years in girls and 14 years in boys and no or partial gonadotropins response to a gonadotropin-releasing hormone stimulation test [14]. The follow-up for each patient included measurements of plasma free thyroxin and cortisol concentrations at 8 a.m. every one or two years, if their concentrations had previously been normal to diagnose delayed deficiency.

Exome sequencing and array-CGH analysis

Exon enrichment was performed as described elsewhere using Agilent SureSelect Human All Exon V4 [15]. Paired-end sequencing was performed on the Illumina HiSeq2000 platform with an average sequencing coverage of x50. Read files were generated from the sequencing platform via the manufacturer's proprietary software. Reads were mapped using the Burrows-Wheeler Aligner and local realignment of the mapped reads around potential insertion/deletion (indel) sites was carried out with the GATK version 1.6. SNP and indel variants were called using the GATK Unified Genotyper for each sample. SNP novelty was determined against dbSNP138. Datasets were filtered for novel or rare (MAF<0.01) variants. Novel and rare variants were analyzed by a range of web-based bioinformatics tools using the EnsEMBL SNP Effect Predictor (http://www.ensembl.org/homosapiens/userdata/uploadvariations). All variants were screened manually against the Human Gene Mutation Database Professional (Biobase) (http://www.biobase-international.com/product/hgmd). In silico analysis was performed to determine the potential pathogenicity of the variants using Polyphen (http://genetics.bwh.harvard.edu/pph), and SIFT (http://sift.jcvi.org/www/SIFT_chr_coords_submit.html) online tools that predict the effect of human mutations on protein function. We focused our analyses on non-synonymous coding, nonsense, and splice site variants, filtering out all known common variations contained in dbSNP (build 138) (www.ncbi.nlm.nih.gov/projects/SNP/), and in the gnomAD database (http://gnomad.broadinstitute.org/). An in-house database of 1100 exomes from control individuals or individuals with unrelated pathologies were also screened for the potential pathogenic variants identified in the PSIS cohort. Variants were confirmed by visual examination using the IGV browser or by Sanger sequencing. Variants were classified according to ACMG guidelines [16]. The parents' DNA was unavailable for study, therefore trio analysis was not possible. Exome datasets were also compared to an in-house control dataset of >700 exomes. Karyotyping was performed using standard methods and chromosomes were observed after G and R banding.

**Results and discussion**

The age at diagnosis ranged from 0.4 to 13.7 years (Table 1). There was no consanguinity nor familial forms of PSIS. The initial symptom leading to the diagnosis of PSIS was hypoglycemia in the youngest patient (case 1), jaundice and ophthalmic symptom in two (cases 2 and 10),
<table><caption>Table 1. Phenotypes of 16 patients with PSIS analysed by exome sequencing.</caption><thead><tr><th>Case</th><th>Ethnic Origin</th><th>Sex</th><th>Age at diagnosis (y)</th><th>Initial symptom</th><th>Pituitary deficits associated with GH deficiency</th><th>Associated phenotypes</th><th>MRI Peculiar features</th><th>PP</th><th>Stalk</th><th>Pituitary height, mm</th></tr></thead><tbody><tr><td>1</td><td>France/Italy</td><td>M</td><td>0.4*</td><td>Hypoglycemia</td><td>T, HH</td><td>Fanconi, microptalmia, moderate hepatic fibrosis, Factor V Leiden mutation</td><td></td><td>E</td><td>not seen</td><td>1</td></tr><tr><td>2</td><td>Asia/France</td><td>M</td><td>0.5</td><td>Neonatal jaundice, ophtalmic</td><td>None, prepubertal</td><td>L optic atrophia, coloboma</td><td>2 posterior ectopic pituitaries</td><td>E</td><td>N</td><td>2</td></tr><tr><td>3</td><td>France</td><td>M</td><td>1.6</td><td>Decreased GR</td><td>None, N puberty</td><td></td><td>2nd anterior pituitary replacing the pituitary stalk</td><td>not seen</td><td>malformed</td><td>2.7</td></tr><tr><td>4</td><td>France</td><td>M</td><td>2.6</td><td>Decreased GR</td><td>None, prepubertal</td><td>Neurodevelopmental syndrome</td><td></td><td>not seen</td><td>N</td><td>4</td></tr><tr><td>5</td><td>France</td><td>M</td><td>3.6</td><td>Decreased GR</td><td>None, N puberty</td><td></td><td></td><td>E</td><td>I</td><td>2</td></tr><tr><td>6</td><td>Portugal</td><td>M</td><td>4.3</td><td>Decreased GR</td><td>None, N puberty</td><td></td><td></td><td>E</td><td>thin</td><td>NA</td></tr><tr><td>7</td><td>France</td><td>F</td><td>4.5</td><td>Decreased GR</td><td>None, early and rapid puberty</td><td></td><td></td><td>N</td><td>I</td><td>4</td></tr><tr><td>8</td><td>France</td><td>M</td><td>4.7</td><td>Decreased GR</td><td>None, prepubertal</td><td></td><td></td><td>E</td><td>not seen</td><td>4</td></tr><tr><td>9</td><td>France</td><td>F</td><td>5.7</td><td>Decreased GR</td><td>T, C**, HH</td><td>L strabismus convergent, unilateral amblyopia, no anosmia</td><td></td><td>E</td><td>not seen</td><td>4</td></tr><tr><td>10</td><td>Marocco</td><td>F</td><td>6.2</td><td>Neonatal jaundice, strabismus</td><td>T, C**, N puberty</td><td>Septo optic dysplasia</td><td>Septum pellucidum, L hypoplasia optic chiasma</td><td>E</td><td>thin</td><td>small</td></tr><tr><td>11</td><td>Portugal</td><td>M</td><td>6.8</td><td>Decreased GR</td><td>None, prepubertal</td><td></td><td></td><td>E</td><td>I</td><td>3</td></tr><tr><td>12</td><td>France</td><td>M</td><td>8.9</td><td>Decreased GR</td><td>None, N puberty</td><td></td><td></td><td>E</td><td>thin</td><td>4</td></tr><tr><td>13</td><td>Tunisia</td><td>M</td><td>9.2</td><td>Decreased GR</td><td>T, C**, HH</td><td></td><td></td><td>E</td><td>I</td><td>NA</td></tr><tr><td>14</td><td>France</td><td>M</td><td>10.4</td><td>Decreased GR</td><td>T, N puberty</td><td></td><td></td><td>E</td><td>not seen</td><td>2.2</td></tr><tr><td>15</td><td>France</td><td>M</td><td>10.6*</td><td>Decreased GR</td><td>T, prepubertal</td><td>Fanconi, nephroblastoma, leukemia and cancer mother</td><td>Brainstem hypoplasia</td><td>E</td><td>not seen</td><td>1</td></tr><tr><td>16</td><td>France</td><td>M</td><td>13.7</td><td>Decreased GR</td><td>None, N puberty</td><td></td><td>Megacisterna magna</td><td>E</td><td>I</td><td>2</td></tr></tbody></table>

Abbreviations: Deficits in GH growth hormone, T thyrotropin, C adrenocorticotropic; HH hypogonadotropic hypogonadism;

GR: growth rate; L: left; N: normal; PP posterior pituitary; E ectopic; I interrupted

*Micropenis, cryptorchidism

**Cortisol at 8 a.m. at 64, 10.7 and 15 ng/mL in cases 9, 10 and 13 respectively

https://doi.org/10.1371/journal.pone.0292664.t001

and decreased growth rate in the 13 others. The GH deficiency was isolated in 10 cases (62.5%), or associated with TSH deficiency isolated in two cases (12.5%) or associated with ACTH deficiency in one case (6.25%) or with HH in one case (6.25%), or multiple deficiencies in two (12.5%). Thus eight patients had normal spontaneous puberty, including a girl who had early and rapid puberty (case 7), 5 cases were in prepubertal age and three cases had HH (18.75% or 27.27% after excluding 5 in prepubertal age). No patient had diabetes insipidus. The associated phenotypes (6 cases, 37.5%) are detailed in the Table 1. Ophthalmic anomalies are present in four patients and Fanconi anemia in two [17].

The genetic cause of most individuals presenting with PSIS with or without associated pituitary or other anomalies is unknown [12, 18]. Both single gene anomalies as well as more complex multigenic inheritance have been proposed to explain the phenotype [19, 20]. The genomic study of this cohort reflects this with pathogenic or likely pathogenic variants identified in only two of the 16 cases suggesting that either multigenic inheritance is involved or that variants in non-coding sequences play an important role (Table 2). The chromosome
<table><caption>Table 2. Gene variants identified in 13 individuals with PSIS that may be associated with the phenotype.</caption><thead><tr><th>Case</th><th>Gene</th><th>Variant/dbSNP<br/>/Zygosity/SIFT/Polyphen2</th><th>MAF and<br/>population</th><th>ClinVar No<br/>/Interpretation</th><th>MI</th><th>Associated phenotypes (MIM)</th><th>ACMG<br/>classification</th></tr></thead><tbody><tr><td>1</td><td>FANCD2</td><td>NM_033084:c.A782T:p.K261M/ rs778289599/ heterozygous/SIFT-D/Polyphen2-P</td><td>0.00002891<br/>Latino/<br/>Admixed<br/>American</td><td>929646<br/>Pathogenic</td><td>AR</td><td>Fanconi anemia,<br/>complementation group D2<br/>(227646)</td><td>VUS</td></tr><tr><td></td><td>DNMT1</td><td>NM_001379:c.C406T:p.R136C/ rs138841970/ heterozygous/SIFT-T/Polyphen2-B</td><td>0.0004258<br/>Europen non-<br/>finnish</td><td>234461<br/>Conflicting</td><td>AD</td><td>Cerebellar ataxia, deafness, and<br/>narcolepsy, autosomal dominant<br/>(604121); Neuropathy, hereditary<br/>sensory, type IE (614116)</td><td>VUS</td></tr><tr><td></td><td>RFWD3</td><td>NM_018124: c.A1364G: p.Y455C/rs200354694/ heterozygous/SIFT-D/Polyphen2-D</td><td>0.0002769<br/>Other</td><td>-</td><td>AR</td><td>Fanconi anemia,<br/>complementation group W<br/>(617784)</td><td>VUS</td></tr><tr><td>2</td><td>DMXL2</td><td>NM_015263: c.4485_4486insTATTTCCTATTAGGTACAACTTT: p.I1496_N1497delinsYFYX/-/heterozygous</td><td>Novel</td><td>-</td><td>AR</td><td>Developmental and epileptic<br/>encephalopathy 81 (618663)<br/>Deafness autosomal dominnt 71<br/>(617605)<br/>Polyendocrine-polyneuropathy<br/>syndrome (616113)</td><td>VUS</td></tr><tr><td></td><td>TMEM67</td><td>NM_001142301:c.C1843A:p.L615I/-/heterozygous/ SIFT-T/Polyphen2-B</td><td>Novel</td><td>-</td><td>AR</td><td>COACH syndrome (216360);<br/>Joubert syndrome 6 (610688);<br/>Meckel syndrome 3 (607361);<br/>Nephronophtisis 11 (613550)</td><td>VUS</td></tr><tr><td></td><td>TMEM67</td><td>NM_001142301: -/heterozygous</td><td>Novel</td><td>-</td><td>AR</td><td>COACH syndrome (216360);<br/>Joubert syndrome 6 (610688);<br/>Meckel syndrome 3 (607361);<br/>Nephronophtisis 11 (613550)</td><td>VUS</td></tr><tr><td>3</td><td>GLI2</td><td>NM_005270:c.1368+1G>A/-/heterozygous</td><td>Novel</td><td>-</td><td>AD</td><td>Culler-Jones syndrome (615849);<br/>Holoprosencephaly 9 (610829)</td><td>Likely<br/>pathogenic</td></tr><tr><td>4</td><td>LHX9</td><td>NM_020204:c.C1063A:p.P355T/-/heterozygous/ SIFT-D/Polyphen2-PrD</td><td>Novel</td><td>-</td><td>-</td><td>-</td><td>VUS</td></tr><tr><td></td><td>CSNK2A1</td><td>NM_177559:c.A593G:p.K198R/ rs869312840/ heterozygous/SIFT-T/Polyphen2-PrD</td><td>0.000008798<br/>European<br/>Non-Finnish</td><td>224790<br/>Conflicting<br/>interpretations of<br/>pathogenicity<br/>Pathogenic; Likely<br/>pathogenic;<br/>Uncertain<br/>significance</td><td>AD</td><td>Okur-Chung<br/>neurodevelopmental syndrome<br/>(617062)</td><td>Pathogenic</td></tr><tr><td>5</td><td>GLI3</td><td>NM_000168:c.A2424G:p.I808M/ rs62622373/ heterozygous/SIFT-T/Polyphen2-D</td><td>0.009359<br/>Ashkenazi<br/>Jewish</td><td>235210<br/>LB</td><td>AD</td><td>Greig cephalopolysyndactyly<br/>syndrome (175700); Pallister-Hall<br/>syndrome (146510); Polydactyly,<br/>postaxial, types A1 and B<br/>(174200); Polydactyly, preaxial,<br/>type IV (174700)</td><td>VUS</td></tr><tr><td>7</td><td>PITX1</td><td>NM_002653:c.403-1->CCGAGCCGCGCGTGCG/-/heterozygous</td><td>Novel</td><td>-</td><td>AD</td><td>Clubfoot, congenital, with or<br/>without deficiency of long bones<br/>and/or mirror-image polydactyly<br/>(119800); Liebenberg syndrome<br/>(186550)</td><td>VUS</td></tr><tr><td></td><td>PITX2</td><td>NM_001204397:c.C501A:p.Y167X/-/heterozygous</td><td>Novel</td><td>-</td><td>AD</td><td>Anterior segment dysgenesis 4<br/>(137600); Axenfeld-Rieger<br/>syndrome, type 1 (180500); Ring<br/>dermoid of cornea (180550)</td><td>VUS</td></tr><tr><td>9</td><td>CC2D2A</td><td>NM_001080522:c.C3055T:p.R1019X/ rs370880399/ heterozygous/</td><td>0.001386<br/>Ashkenazi<br/>Jewish</td><td>217602:<br/>Pathogenic/likely<br/>pathogenic</td><td>AR</td><td>COACH syndrome (216360);<br/>Joubert syndrome 9 (612285)<br/>Meckel syndrome (612284)</td><td>VUS</td></tr><tr><td></td><td>HESX1</td><td>NM_003865:c.G200C:p.S67T/ rs141863326/ heterozygous/SIFT-T/Polyphen2-B</td><td>0.0006206<br/>South Asian</td><td>289279<br/>Uncertain</td><td>AD/<br/>AR</td><td>Pituitary hormone deficiency,<br/>combined, 5 (182230)</td><td>VUS</td></tr></tbody></table>

(Continued)
<table><caption>**Table 2.** (Continued)</caption><thead><tr><th>Case</th><th>Gene</th><th>Variant/dbSNP<br/>/Zygosity/SIFT/Polyphen2</th><th>MAF and<br/>population</th><th>ClinVar No<br/>/Interpretation</th><th>MI</th><th>Associated phenotypes (MIM)</th><th>ACMG<br/>classification</th></tr></thead><tbody><tr><td></td><td>PTCH1</td><td>NM_001083607:c.G2032A:p.V678M/ rs201125580/ heterozygous/SIFT-D/Polyphen2-PrD</td><td>0.004051<br/>Ashkenazi<br/>Jewish</td><td>41655<br/>Conflicting</td><td>AD</td><td>Holoprosencephaly 7 (610828)</td><td>VUS</td></tr><tr><td></td><td>HS6ST1</td><td>NM_004807:c.C652T:p.P218S/ rs200268730/ heterozygous/SIFT-T/Polyphen2-PrD</td><td>0.003100<br/>European<br/>Non-Finnish</td><td>1297575<br/>Conflicting</td><td>AD</td><td>Hypogonadotropic<br/>hypogonadism 15 with or without<br/>anosmia (614880)</td><td>VUS</td></tr><tr><td rowspan="3">10</td><td>CHD7</td><td>NM_017780:c.C8416G:p.L2806V/ Rs45521933/ heterozygous/SIFT-T/Polyphen2-P</td><td>0.004017<br/>Latino/<br/>Admixed<br/>American</td><td>95814<br/>LB/B</td><td>AD</td><td>CHARGE syndrome (214800);<br/>Hypogonadotropic<br/>hypogonadism 5 with or without<br/>anosmia (612370)</td><td>VUS</td></tr><tr><td>IL17RD</td><td>NM_017563:c.C470T:p.T157M/ rs200321574/ heterozygous/SIFT-D/Polyphen2-D</td><td>0.0001387<br/>Other</td><td>-</td><td>AR/<br/>AD</td><td>Hypogonadotropic<br/>hypogonadism 18 with or without<br/>anosmia (606807)</td><td>VUS</td></tr><tr><td>ARID1A</td><td>NM_139135:exon1:c.G376A:p.G126S/ rs1400214289/heterozygous/SIFT-D/Polyphen2-PD</td><td>0.0001971<br/>Latino/<br/>Admixed<br/>American</td><td>1197625<br/>LB</td><td>AD</td><td>Coffin-Siris syndrome 2 (614607)</td><td>VUS</td></tr><tr><td>11</td><td>TBCE</td><td>NM_003193:c.C89T:p.P30L/-/heterozygous/ SIFT-D/Polyphen2-D</td><td>Novel</td><td>-</td><td>AR</td><td>Encephalopathy progressive, with<br/>amyotrophy and optic atrophy<br/>(617207); Hypoparathyroidism-<br/>retardation-dysmorphism<br/>syndrome (241410); Kenny-<br/>Caffey syndrome type 1 (244460)</td><td>VUS</td></tr><tr><td>12</td><td>ARNT2</td><td>NM_014862:c.G1707T:p.Q569H/ rs145379118/ heterozygous/SIFT-D/Polyphen2-B</td><td>0.005086<br/>European<br/>Non-Finnish</td><td>791642<br/>LB</td><td>AR</td><td>Webb-Dattani syndrome<br/>(615926)</td><td>VUS</td></tr><tr><td>13</td><td>PROP1</td><td>NM_006261:c.C425T:p.A142V/ rs143790367/ heterozygous/SIFT-T/Polyphen2-B</td><td>0.006080<br/>Ashkenazi<br/>Jewish</td><td>196432<br/>Conflicting</td><td>AR</td><td>Pituitary hormone deficiency,<br/>combined, 2<br/>(262600)</td><td>VUS</td></tr><tr><td></td><td>KISS1R</td><td>NM_032551:c.G565A:p.A189T/ rs73507527/ heterozygous/ SIFT-T/Polyphen2-B</td><td>0.06569<br/>African/<br/>African<br/>Americans</td><td>235657<br/>B/LB</td><td>AR</td><td>Hypogonadotropic<br/>hypogonadism 8 with or without<br/>anosmia (614837)</td><td>VUS</td></tr><tr><td></td><td>GLI2</td><td>NM_005270:c.G2159A:p.R720H/ rs149091975/ heterozygous</td><td>0.001366<br/>African/<br/>African<br/>American</td><td>259723<br/>Uncertain<br/>significance</td><td>AD</td><td>Culler-Jones syndrome (615849);<br/>Holoprosencephaly 9 (610829)</td><td>VUS</td></tr><tr><td>14</td><td>DMXL2</td><td>NM_015263:c.88-2-&gt;TTTTTTTTTTTTT/-/ homozygous</td><td>Novel</td><td>-</td><td>AR</td><td>Developmental and epileptic<br/>encephalopathy 81 (618663)<br/>Deafness autosomal dominant 71<br/>(617605)<br/>Polyendocrine-polyneuropathy<br/>sd (616113)</td><td>VUS</td></tr><tr><td>16</td><td>GLI2</td><td>GLI2:NM_005270:exon12:c.G2041A:p.V681M/ rs551617843/SIFT-D/Polyphen2-B</td><td>0.0003673<br/>Latino/<br/>Admixed<br/>American</td><td>1411228<br/>uncertain</td><td>AD</td><td>Culler-Jones syndrome (615849);<br/>Holoprosencephaly 9 (610829)</td><td>VUS</td></tr><tr><td></td><td>PTCH1</td><td>NM_001083607:c.A3494G:p.Y1165C/rs147067171/ heterozygous/SIFT-T/Polyphen2-D</td><td>0.001075<br/>Ashkenazi<br/>Jewish</td><td>132723<br/>Conflicting (B)</td><td>AD</td><td>Holoprosencephaly 7 (610828)</td><td>VUS</td></tr><tr><td></td><td>PTCH1</td><td>NM_001083607:c.C3871T:p.R1291W/rs143464326/ heterozygous/SIFT-T/Polyphen2-B</td><td>0.005945<br/>South Asian</td><td>41666<br/>Conflicting</td><td>AD</td><td>Holoprosencephaly 7 (610828)</td><td>VUS</td></tr></tbody></table>

(Continued)
<table><caption>**Table 2.** (Continued)</caption><thead><tr><th>Case</th><th>Gene</th><th>Variant/dbSNP<br/>/Zygosity/SIFT/Polyphen2</th><th>MAF and<br/>population</th><th>ClinVar No<br/>/Interpretation</th><th>MI</th><th>Associated phenotypes (MIM)</th><th>ACMG<br/>classification</th></tr></thead><tbody><tr><td></td><td>FGF17</td><td>NM_003867:c.C634T:p.P212S/rs778556940/<br/>heterozygous/SIFT-T/Polyphen2-PoB</td><td>0.000209<br/>Latino/<br/>Admixed<br/>American</td><td>-</td><td>AD</td><td>Hypogonadotropic<br/>hypogonadism 20 with or without<br/>anosmia (615270)</td><td>VUS</td></tr></tbody></table>

MAF, Minor Allelic Frequency (the population showing the highest MAF is indicated); MI, known mode of inheritance of the phenotype; AR, autosomal recessive; AD, autosomal dominant; T, tolerated; B, benign; PoB probably benign; LB Likely benign; D, deleterious; PrD probably damaging; VUS, variant of unknown significance

https://doi.org/10.1371/journal.pone.0292664.t002

complement of all individuals in the study was found to be normal following standard karyotype analysis.

In 13 patients variants were identified that may contribute to the phenotype. Genetic variants associated with the phenotype could not be identified in candidate genes in the cases 6,8 and 15. In only one of patient was a variant classified as pathogenic. This child (case 4) presented with the typical clinical presentation of Okur-Chung neurodevelopmental syndrome with delay in walk (2.4 years), hypotonia and peculiar form of autism. This is a very rare autosomal dominant developmental disorder characterized by neurological anomalies with variable dysmorphic features, hypotonia, skeletal anomalies and cardiac anomalies. The phenotype is highly variable including brain MRI while others do not exhibit any abnormality in the brain architecture [21]. Okur-Chung neurodevelopmental syndrome is caused by *de novo* variants in the *CSNK2A1* gene, which encodes the alpha subunit of protein kinase CK2, a highly conserved serine/threonine protein kinase that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine [22]. The p.K198R variant is a recurrent mutation with at least eight other cases reported in the literature with this pathogenic variant [23–27]. The K198 residue is located within the kinase domain and specifically within the activation segment of CK2 [28]. Although p. K198R was originally considered to be a loss-of-function variant more recent studies have indicated that variant does not result in complete loss of kinase activity, but rather a shift in substrate specificity [28]. In this case presented here we do not have access to the parents’ DNA to determine if the variant is *de novo* but based on previously published cases associated with this missense variant together with functional studies we classified this variant as pathogenic.

One of the main findings in recent years concerning the genetic factors involved in PSIS, and other pituitary anomalies, is the link to genes known to cause holoprosencephaly. This includes for example the genes *CDON*, *GLI2*, *SHH* and *TGIF1* [11, 12, 29]. In this cohort we identified several variants in the holoprosencephaly genes *PTCH1* and *GLI2* that may contribute to PSIS. However, in only one case (case 3) could the variant be classified as likely pathogenic. He has a peculiar aspect on MRI with second anterior pituitary like replacing the pituitary stalk. This child carried a novel and essential splice site variant that is predicted to be a loss-of-function (LOF) variant in the *GLI2* gene. Pathogenic, heterozygous variants in *GLI2* are associated with either autosomal dominant Culler-Jones Syndrome or holoprosencephaly 9 with considerable phenotypic heterogeneity [30]. The most common features associated with *GLI2* LOF variants are polydactyly, hypopitutarism (isolated or combined) and abnormal pituitary imaging. These features are observed in approximately 50% of cases and the polydactyly is often the mildest phenotypic expression and often absent or not reported in parents carrying known pathogenic variants transmitted to their more severely affected child [30].
Indeed, *GLI2* variants have also been associated with PSIS [12, 29, 31] and hence we consider this variant to be likely pathogenic.

The role of other holoprosencephaly gene variants that we identified is less clear. Patient 16 carries two variants in the *PTCH1* gene. He had megacisterna magna on his MRI. Pathogenic heterozygous variants in *PTCH1*, a gene that encodes the receptor for the secreted hedgehog ligands are responsible for an autosomal dominant form of holoprosencephaly that includes panhypopituitarism [32]. Heterozygous variants have also been proposed to cause PSIS but currently the evidence for pathogenicity is limited [29].

For the other variants identified in this study the relationship with the PSIS phenotype is more difficult to determine. Patient 7 carries two heterozygous, predicted loss-of-function variants in the *PITX1* and *PITX2* genes (Table 2). Variants in both of these genes are associated with complex autosomal dominant congenital disorders [33]. *PITX2* plays a role during ontogeny of the pituitary gland and other anterior structures, including the eye and patients with heterozygous pathogenic *PITX2* variants present with eye, pituitary craniofacial, dental, cardiac, and umbilical anomalies [33]. However, patient 7, despite carrying a nonsense variant in *PITX2* only presented with a decreased growth rate, early puberty and PSIS. No eye nor other pituitary anomalies were observed. Since the patient carries a novel loss-of-function nonsense variant, it is possible that this case represents a very mild expression of the *PITX2* phenotype.

Patient 1 was diagnosed with PSIS associated with Fanconi anemia. The child carried a known heterozygous pathogenic variant in *FANCD2*, however Fanconi anemia due to *FANCD2* variants is autosomal recessive [34]. It is therefore possible that the affected child carried a second variant, perhaps non-coding that was not covered by the exome sequencing, or the phenotype may be due to the combination of *FANCD2* with variants in the *DNMT1* or *RFWD3* genes (Table 2). Biallelic variants in the latter were reported in a familial form of Fanconi anemia [35]. The clinical description of patient reported by Knies et al., is similar to patient 1. They both presented with Fanconi anemia, intrauterine growth retardation, left kidney dysplasia, left radius hypoplasia, absent thumbs, GH deficiency, ectopic posterior pituitary and with no intellectual disability.

Many of the remaining variants were classified as variant of uncertain significance (VUS) either because the allelic frequency of the variant in the general population was too high to cause of the phenotype (e.g. KISS1R p.A189T), and/or the variant was monoallelic, where the disease is associated with biallelic variants (e.g. CC2D2A, p.1019X) and/or the variant was not predicted to be pathogenic by predictive software (e.g. KISS1R p.A189T). This includes variants in the genes associated with HH. Although we identified rare or novel missense variants in several HH genes (e.g. *FGF17*, *HS6ST1*, *KISS1R*, *CHD7*, *IL17RD*) [36] definitively linking them to the PSIS phenotype is premature.

## Conclusions

We previously reported that in many individuals PSIS may be considered as part of the phenotypic spectrum of other known genetic syndromes rather than as a specific clinical entity. In these individuals the genetic cause can often be explained as the genetic syndrome is well defined (e.g. FANCA) [12]. The major challenge is to identify pathogenic variants in cases with isolated PSIS. As shown here and elsewhere [18, 37, 38], in such individuals the diagnostic yield is currently very low.

## Author Contributions

**Conceptualization:** Raja Brauner, Ken McElreavey.
**Data curation:** Joelle Bignon-Topalovic, Anu Bashamboo.

**Investigation:** Raja Brauner.

**Writing – original draft:** Raja Brauner, Ken McElreavey.

## References

1. Argyropoulou M, Perignon F, Brauner R, Brunelle F. Magnetic resonance imaging in the diagnosis of growth hormone deficiency. J Pediatr 1992 Jun; 120(6):886-891. https://doi.org/10.1016/s0022-3476(92)81955-9 PMID: 1593348.

2. Castinetti F, Saveanu A, Reynaud R, Quentien MH, Buffin A, Brauner R et al. A novel dysfunctional LHX4 mutation with high phenotypic variability in patients with hypopituitarism. J Clin Endocrinol Metab 2008; 93(7):2790-2799. https://doi.org/10.1210/jc.2007-2389 PMID: 18445675.

3. Diaczok D, Romero C, Zunich J, Marshall I, Radovick S. A novel dominant negative mutation of OTX2 associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab 2008; 93(11):4351-4359. https://doi.org/10.1210/jc.2008-1189 PMID: 18728160.

4. McNay DEG, Turton JP, Kelberman D, Woods KS, Brauner R, Papadimitriou A et al. HESX1 mutations are an uncommon cause of septo-optic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007; 92(2):691-697. https://doi.org/10.1210/jc.2006-1609 PMID: 17148560.

5. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, Palmer R et al. Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 2005; 76(5):833-849. https://doi.org/10.1086/430134 PMID: 15800844.

6. McCormack SE, Li D, Kim YJ, Lee JY, Kim SO, Rapaport R et al. Digenic Inheritance of PROKR2 and WDR11 mutations in pituitary stalk interruption syndrome. J Clin Endocrinol Metab 2017; 102(7):2501-2507. https://doi.org/10.1210/jc.2017-00332 PMID: 28453858.

7. Karaca E, Buyukkaya R, Pehlivan D, Charng WL, Kaykasli KO, Bayram Y et al. Whole-exome sequencing identifies homozygous GPR161 mutation in a family with pituitary stalk interruption syndrome. J Clin Endocrinol Metab 2015; 100(1): E140-E147. https://doi.org/10.1210/jc.2014-1984 PMID: 25322266.

8. El Chehadeh-Djebbar S, Callier P, Masurel-Paulet A, Bensignor C, Méjean N, Payet M, et al. 17q21.31 microdeletion in a patient with pituitary stalk interruption syndrome. Eur J Med Genet 2011; 54(3):369-373. https://doi.org/10.1016/j.ejmg.2011.03.001 PMID: 21397059.

9. Tatsi C, Sertedaki A, Voutetakis A, Valavani E, Magiakou MA, Kanaka-Gantenbein C et al. Pituitary stalk interruption syndrome and isolated pituitary hypoplasia may be caused by mutations in holoprosencephaly-related genes. J Clin Endocrinol Metab 2013; 98(4):E779-E784. https://doi.org/10.1210/jc.2012-3982 PMID: 23476075.

10. França MM, Jorge AA, Carvalho LR, Costalonga EF, Vasques GA, Leite CC et al. Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly. J Clin Endocrinol Metab 2010; 95(11):E384-E391. https://doi.org/10.1210/jc.2010-1050 PMID: 20685856.

11. Bashamboo A, Bignon-Topalovic J, Rouba H, McElreavey K, Brauner R. A nonsense mutation in the hedgehog receptor CDON associated with pituitary stalk interruption syndrome. J Clin Endocrinol Metab 2016; 101(1):e12-e15. https://doi.org/10.1210/jc.2015-2995 PMID: 26529631.

12. Brauner R, Bignon-Topalovic J, Bashamboo A, McElreavey K. Pituitary stalk interruption syndrome is characterized by genetic heterogeneity. PLoS ONE 2020 15(12): e0242358. https://doi.org/10.1371/journal.pone.0242358 PMID: 33270637

13. Pham L-L, Lemaire P, Harroche A, Souberbielle J-C, Brauner R. Pituitary stalk interruption syndrome in 53 postpubertal patients: factors influencing the heterogeneity of its presentation. PloS One 2013 8: e53189. https://doi.org/10.1371/journal.pone.0053189 PMID: 23308160

14. Corvest V, Lemaire P, Brailly-Tabard S, Brauner R. Puberty and inhibin B in 35 adolescents with pituitary stalk interruption syndrome. Front Pediatr 2020; 8:304. Published 2020 Jun 11. https://doi.org/10.3389/fped.2020.00304 PMID: 32596193.

15. Murphy MW, Lee JK, Rojo S, Gearhaert MD, Kurahashi K, Banerjee S et al. An ancient protein-DNA interaction underlying metazoan sex determination. Nat Struct Mol Biol 2015 Jun; 22(6):442-451. Epub 2015 May 25. https://doi.org/10.1038/nsmb.3032 PMID: 26005864.

16. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015 May; 17(5):405-424. https://doi.org/10.1038/gim.2015.30 PMID: 25741868.
17. Dupuis-Girod S, Gluckman E, Souberbielle JC, Brauner R. Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia. J Pediatr 2001; 138(1):129-133. https://doi.org/10.1067/mpd.2001.109200 PMID: 11148528.

18. Jullien N, Saveanu A, Vergier J, Marquant E, Quentien MH, Castinetti F et al.; Genhypopit Network. Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort. Clin Endocrinol (Oxf) 2021 Feb; 94(2):277-289. Epub 2020 Dec 21. https://doi.org/10.1111/cen.14355 PMID: 33098107.

19. Guo QH, Wang CZ, Wu ZQ, Qin Y, Han BY, Wang AP, et al. Multi-genic pattern found in rare type of hypopituitarism: a whole-exome sequencing study of Han Chinese with pituitary stalk interruption syndrome. J Cell Mol Med 2017 Dec; 21(12):3626-3632. https://doi.org/10.1111/jcmm.13272 PMID: 28707430.

20. Bashamboo A, Bignon-Topalovic J, Moussi N, McElreavey K, Brauner R. Mutations in the human ROBO1 gene in pituitary stalk interruption syndrome. J Clin Endocrinol Metab 2017; 102(7):2401-2406. https://doi.org/10.1210/jc.2016-1095 PMID: 28402530.

21. Okur V, Cho MT, Henderson L, Retterer K, Schneider M, Sattler S, et al. De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features. Hum Genet 2016 Jul; 135(7):699-705. https://doi.org/10.1007/s00439-016-1661-y PMID: 27048600.

22. St-Denis NA, Derksen DR, Litchfield DW. Evidence for regulation of mitotic progression through temporal phosphorylation and dephosphorylation of CK2alpha. Mol Cell Biol 2009 Apr; 29(8):2068-2081. Epub 2009 Feb 2. https://doi.org/10.1128/MCB.01563-08 PMID: 19188443.

23. Xu S, Lian Q, Wu J, Li L, Song J. Dual molecular diagnosis of tricho-rhino-phalangeal syndrome type I and Okur-Chung neurodevelopmental syndrome in one Chinese patient: a case report. BMC Med Genet 2020 Aug 3; 21(1):158. https://doi.org/10.1186/s12881-020-01096-w PMID: 32746809.

24. Akahira-Azuma M, Tsurusaki Y, Enomoto Y, Mitsui J, Kurosawa K. Refining the clinical phenotype of Okur-Chung neurodevelopmental syndrome. Hum Genome Var 2018 Mar 29; 5:18011. eCollection 2018. https://doi.org/10.1038/hgv.2018.11 PMID: 29619237.

25. Nakashima M, Tohyama J, Nakagawa E, Watanabe Y, Siew CG, Kwong CS, et al. Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures. J Hum Genet 2019 Apr; 64(4):313-322. Epub 2019 Jan 17. https://doi.org/10.1038/s10038-018-0559-z PMID: 30655572.

26. Owen CI, Bowden R, Parker MJ, Patterson J, Patterson J, Price S, et al. Deciphering Developmental Disorders Study; Tatton-Brown K. Extending the phenotype associated with the CSNK2A1-related Okur-Chung syndrome-A clinical study of 11 individuals. Am J Med Genet A 2018 May; 176(5):1108-1114. Epub 2018 Jan 31. https://doi.org/10.1002/ajmg.a.38610 PMID: 29383814.

27. Chiu ATG, Pei SLC, Mak CCY, Leung GKC, Yu MHC, Lee SL and et al. Okur-Chung neurodevelopmental syndrome: Eight additional cases with implications on phenotype and genotype expansion. Clin Genet 2018 Apr; 93(4):880-890. Epub 2018 Feb 13. https://doi.org/10.1111/cge.13196 PMID: 29240241.

28. Caefer DM, Phan NQ, Liddle JC, Balsbaugh JL, O'Shea JP, Tzingounis AV et al. The Okur-Chung Neurodevelopmental Syndrome Mutation CK2<sup>K198R</sup> Leads to a Rewiring of Kinase Specificity. Front Mol Biosci 2022 Apr 19; 9:850661. eCollection 2022. https://doi.org/10.3389/fmolb.2022.850661 PMID: 35517865.

29. Fang X, Zhang Y, Cai J, Lu T, Hu J, Yuan F, et al. Identification of novel candidate pathogenic genes in pituitary stalk interruption syndrome by whole-exome sequencing. J Cell Mol Med 2020 Oct; 24(20):11703-11717. Epub 2020 Aug 31. https://doi.org/10.1111/jcmm.15781 PMID: 32864857.

30. Corder M. L., Berland S., Førsvoll J. A., Banerjee I., Murray P., Bratland E., et al. Truncating and zinc-finger variants in GLI2 are associated with hypopituitarism. Am J Med Gen Part A, 2022; 188A:1065-1074. https://doi.org/10.1002/ajmg.a.62611 PMID: 34921505

31. Zwaveling-Soonawala N, Alders M, Jongejan A, Kovacic L, Duijkers FA, Maas SM, et al. Clues for Polygenic Inheritance of Pituitary Stalk Interruption Syndrome From Exome Sequencing in 20 Patients. J Clin Endocrinol Metab 2018 Feb 1; 103(2):415-428. https://doi.org/10.1210/jc.2017-01660 PMID: 29165578.

32. Ming JE, Kaupas ME, Roessler E, Brunner HG, Golabi M, Tekin M, et al. Mutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly. Hum Genet 2002 Apr; 110 (4):297-301. https://doi.org/10.1007/s00439-002-0695-5 PMID: 11941477.

33. Tran TQ, Kioussi C. Pitx genes in development and disease. Cell Mol Life Sci 2021 Jun; 78(11):4921-4938. Epub 2021 Apr 12. https://doi.org/10.1007/s00018-021-03833-7 PMID: 33844046.

34. Kalb R, Neveling K, Hoehn H, Schneider H, Linka Y, Batish SD, et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients
with severe phenotype. Am J Hum Genet 2007 May; 80(5):895-910. Epub 2007 Apr 6. https://doi.org/10.1086/517616 PMID: 17436244.

35. Knies K, Inano S, Ramírez MJ, Ishiai M, Surrallés J, Takata M, Schindler D. Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia. J Clin Invest 2017 Aug 1; 127(8):3013-3027. Epub 2017 Jul 10. https://doi.org/10.1172/JCI92069 PMID: 28691929.

36. Al Sayed Y, Howard SR. Panel testing for the molecular genetic diagnosis of congenital hypogonadotropic hypogonadism—a clinical perspective. Eur J Hum Genet 2022 Dec 15. https://doi.org/10.1038/s41431-022-01261-0 PMID: 36517585.

37. Silva TS, Faucz FR, Hernández-Ramírez LC, Pankratz N, Lane J, Kay DM et al. Whole Exome Sequencing in Patients With Ectopic Posterior Pituitary. Journal of the Endocrine Society 2022, 6, 1-12 https://doi.org/10.1210/jendso/bvac116 PMID: 36042976.

38. Sertedaki A, Tatsi EB, Vasilakis JA, Fylaktou I, Nikaina E, Iacovidou N et al. Whole exome sequencing points towards a multi-gene synergistic action in the pathogenesis of congenital combined pituitary hormone deficiency. Cells 2022, 11, 2088. https://doi.org/10.3390/cells11132088 PMID: 35805171.